DE19718924A1 - Apparatus to recover component fractions from exhaled air - Google Patents
Apparatus to recover component fractions from exhaled airInfo
- Publication number
- DE19718924A1 DE19718924A1 DE1997118924 DE19718924A DE19718924A1 DE 19718924 A1 DE19718924 A1 DE 19718924A1 DE 1997118924 DE1997118924 DE 1997118924 DE 19718924 A DE19718924 A DE 19718924A DE 19718924 A1 DE19718924 A1 DE 19718924A1
- Authority
- DE
- Germany
- Prior art keywords
- ingredients
- exhaled air
- nonwoven fabric
- porous materials
- nonwoven
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000011148 porous material Substances 0.000 claims abstract description 9
- 239000000443 aerosol Substances 0.000 claims abstract description 8
- 238000002965 ELISA Methods 0.000 claims abstract description 6
- 238000003127 radioimmunoassay Methods 0.000 claims abstract description 5
- 239000000835 fiber Substances 0.000 claims abstract description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 3
- 239000004615 ingredient Substances 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 239000004745 nonwoven fabric Substances 0.000 claims description 9
- 210000004072 lung Anatomy 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 2
- 239000012209 synthetic fiber Substances 0.000 claims description 2
- -1 natural silk) Polymers 0.000 claims 4
- 229920001410 Microfiber Polymers 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 239000005550 inflammation mediator Substances 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 239000003658 microfiber Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229920002994 synthetic fiber Polymers 0.000 claims 1
- 239000000126 substance Substances 0.000 description 8
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/497—Physical analysis of biological material of gaseous biological material, e.g. breath
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Die Erfindung betrifft eine Vorrichtung zur Gewinnung von Inhaltsstoffen der Ausatemluft nach dem Oberbegriff des Haupt anspruches sowie ein Verfahren zur Isolierung dieser Inhalts stoffe und deren Verwendung zur Diagnostik und Therapieüber wachung von Krankheiten.The invention relates to a device for the extraction of Inhaled air ingredients according to the generic term of the main claim and a method for isolating this content substances and their use for diagnosis and therapy disease monitoring.
Bisherige Verfahren gehen davon aus, daß die Lungenin haltsstoffe in der Ausatemluft allein durch Kondensation an einer Kühlfläche mit hoher Effektivität isoliert und ange reichert werden können.Previous procedures assume that the lung substances in the exhaled air only through condensation a cooling surface with high effectiveness isolated and ange can be enriched.
Aus WO 91/05 255 A1 ist ein Verfahren zur Diagnose des Gesundheitszustandes sowie zur Therapieüberwachung und zur Verlaufskontrolle von Krankheiten, speziell der Lunge und der Atemwege, bekannt, wonach nichtflüchtige - gegebenenfalls zusammen mit endogenen und exogenen - Stoffen in der mensch lichen Ausatemluft durch Kondensation und Ausfrieren an einer mit flüssigem Stickstoff gekühlten Fläche isoliert werden.WO 91/05 255 A1 describes a method for diagnosing the Health status as well as for therapy monitoring and for Monitoring the course of diseases, especially the lungs and Respiratory system, known after which non-volatile - if necessary together with endogenous and exogenous substances in humans exhaled air through condensation and freezing on one surface cooled with liquid nitrogen.
Der Nachteil dieses Verfahrens liegt in dem großen apparativen Aufwand, der Gewinnung geringer Mengen an Probenmaterial und dem Umgang mit flüssigem Stickstoff, der besondere Sicher heitsvorkehrungen erfordert.The disadvantage of this method lies in the large apparatus Effort, the extraction of small amounts of sample material and handling liquid nitrogen, special safety precautions required.
Es ist weiterhin ein Verfahren zur Gewinnung von Atemkondensat bekannt (Am. Rev. Repir. Dis., Vol. 148, 1993, 955-960), bei dem über ein Mundstück durch ein mit Eis gekühltes Rohr aus PVC ausgeatmet wird. Das Atemkondensat tropft dabei in eine eisgekühlte Flasche. Der Nachteil dieses Verfahrens ist, daß lediglich Stoffe aus der Atemluft abgeschieden werden, die bei ca. 0°C kondensieren. Dadurch ist die Anwendung des Verfahrens erheblich eingeschränkt. It is also a method of obtaining breath condensate known (Am. Rev. Repir. Dis., Vol. 148, 1993, 955-960), at through a mouthpiece through a tube cooled with ice PVC is exhaled. The breath condensate drips into one iced bottle. The disadvantage of this method is that only substances can be separated from the air we breathe Condense approx. 0 ° C. This is the application of the procedure significantly restricted.
Ein weiteres Verfahren (DE 195 05 504 A1) und eine ent sprechende Vorrichtung (DE G 94 21 065.0) zur Gewinnung von Atemkondensat verwendet ein doppelwandiges gekühltes Probe sammelrohr, das an den Enden mit einem Ein- und Auslaufventil versehen ist. Die Kühlung des Probensammelrohres erfolgt mit einem Kühlthermostaten, wobei das Kühlmittel im Gegenstrom prinzip durch den Kühlmantel geführt wird. Dabei wird die Innenwand des Kühlrohres auf -10 bis -25°C abgekühlt. Bei der Ausatmung in das Probensammelrohr wird das Atemkondensat auf der Innenfläche des mit einem PTFE- Rohr ausgekleideten Kühlers ausgefroren.Another method (DE 195 05 504 A1) and an ent speaking device (DE G 94 21 065.0) for the extraction of Breath condensate uses a double-walled cooled sample collecting tube, which at the ends with an inlet and outlet valve is provided. The sample collection tube is cooled with a cooling thermostat, the coolant in counterflow principle is guided through the cooling jacket. The Cooled inner wall of the cooling pipe to -10 to -25 ° C. At exhaling into the sample collection tube becomes the breath condensate on the inner surface of the one lined with a PTFE tube Frozen cooler.
Der Nachteil dieses Verfahrens ist der große apparative Auf wand, die lange Zeit bis zur Erreichung des Betriebszustandes und die Abscheidung geringer Mengen an Atemkondensat auf einer relativ großen Fläche. Dadurch wird die Probenentnahme umständlich und verlustreich. Gleichzeitig schränkt der hohe Zeitbedarf bis zur Erreichung des Betriebszustandes der Vorrichtung die Anwendung in der klinischen und ärztlichen Praxis ein.The disadvantage of this method is the large equipment wall, the long time until the operating state is reached and the deposition of small amounts of breath condensate on one relatively large area. This will take the sample cumbersome and lossy. At the same time, the high limits Time required to reach the operating state of the Device for use in clinical and medical Practice one.
Bekannt ist weiterhin eine Vorrichtung zur Gewinnung der Inhaltsstoffe der Ausatemluft aus WO 97/04310 A1 und weiter ausgestaltet durch DE 197 03 708.9, bei der auf einer dünnen Folie, die mittels Vakuum oder selbsthaftend auf der Ober fläche der Kaltseite eines Peltierelementes fixiert ist, das Atemkondensat sich in gefrorener Form niederschlägt.A device for obtaining the is also known Inhaled air ingredients from WO 97/04310 A1 and further designed by DE 197 03 708.9, in which on a thin Foil applied by vacuum or self-adhesive on the upper surface of the cold side of a Peltier element is fixed Breath condensate condenses in frozen form.
Generell haben alle Verfahren, die allein auf der Abscheidung von Inhaltsstoffen der Ausatemluft an gekühlten Flächen basie ren, den Nachteil, daß in Abhängigkeit der Vorrichtung und den Temperaturen zwar unterschiedliche Mengen an Lungeninhalts stoffen abgeschieden werden, jedoch die Abscheidungseffizienz sehr gering ist.Generally, all procedures are based solely on the deposition of ingredients in the exhaled air on cooled surfaces ren, the disadvantage that depending on the device and the Temperatures have different amounts of lung content substances are separated, but the separation efficiency is very low.
Dies ist dadurch bedingt, daß weniger Lungenaerosoltröpfchen im Verhältnis zu Wasserdampf abgeschieden werden, so daß es zu einer starken Verdünnung der Lungeninhaltsstoffe im Atemkon densat kommt und die Anwendung des so gewonnenen Atemkonden sates in Verbindung mit der Analyse von bestimmten Lungenin haltsstoffen zur Diagnostik und Therapiekontrolle von Krank heiten, speziell von Lungenerkrankungen, einschränkt.This is due to the fact that fewer lung aerosol droplets be separated in relation to water vapor, so that it too a strong thinning of the pulmonary constituents in the breath con densat comes and the application of the breath condensate obtained in this way sates in connection with the analysis of certain lungs substances for diagnosis and therapy control of sick units, especially of lung diseases.
Der Erfindung liegt das Problem zugrunde, eine apparativ ein fache und effiziente Vorrichtung zur Gewinnung von Inhalts stoffen der Ausatemluft zu schaffen und gleichzeitig die Isolierung durch ein einfaches Verfahren zu ermöglichen sowie die Verwendung der isolierten Inhaltsstoffe zur Diagnose und Therapieüberwachung zu erweitern.The invention is based on the problem of an apparatus fold and efficient device for obtaining content to create substances of the exhaled air and at the same time the To allow isolation by a simple process as well the use of the isolated ingredients for diagnosis and Extend therapy monitoring.
Erfindungsgemäß wird das Problem mit den Merkmalen des Kennzeichenteiles des Hauptanspruches gelöst. Die Merkmale der Unteransprüche gestalten die Erfindung in vorteilhafterweise aus. Die Verfahrensmerkmale ermöglichen die Isolierung der als Aerosol vorliegenden Inhaltsstoffe. Die Verwendung der gewon nenen Inhaltsstoffe als Aerosol ermöglicht eine Erweiterung der Diagnose und Therapieüberwachung von Krankheiten.According to the invention the problem with the features of Characteristic part of the main claim solved. The characteristics of the Subclaims advantageously design the invention out. The process features allow the isolation of the as Aerosol present ingredients. The use of the won The ingredients as an aerosol enable expansion diagnosis and therapy monitoring of diseases.
Die Vorteile der Erfindung sind darin begründet, daß der Auf wand für die Apparatur sehr gering ist und diese unmittelbar ohne Vorbereitungen einsatzfähig ist.The advantages of the invention are that the on wall for the equipment is very low and this directly is operational without preparations.
Im Gegensatz zum Stand der Technik wird bei vermindertem Auf wand für die Apparatur und ohne Kühlung eine etwa 4-fach höhere Abscheidungsrate von Inhaltsstoffen der Ausatemluft er reicht.In contrast to the prior art, with reduced opening wall for the equipment and without cooling about 4 times higher separation rate of ingredients in exhaled air enough.
Von ebenfalls besonderer Bedeutung ist die Tatsache, daß die Lungeninhaltsstoffe als Aerosol im Faservlies in hoher Kon zentration ohne Verdünnung durch kondensierten Wasserdampf abgeschieden werden.Of particular importance is the fact that the Lung contents as aerosol in the fiber fleece in high con concentration without dilution by condensed water vapor be deposited.
Die Erfindung soll nachstehend durch Ausführungsbeispiele mit entsprechender Isolierung der Inhaltsstoffe und dem Therapie monitoring näher erläutert werden.The invention is intended to be described in the following by means of exemplary embodiments appropriate isolation of the ingredients and the therapy monitoring are explained in more detail.
In der zugehörigen Zeichnung ist die Vorrichtung vereinfacht dargestellt.The device is simplified in the accompanying drawing shown.
Vor einem Filterhalteteil 5 mit Faservlies 6 ist ein Mundstück 2 mit einem Einatemventil 3 und Auslaßventil 4 angeordnet. Das Faservlies 6 kann aus Natur-, Kunst- oder Glasfasern be stehen. Auch ist es möglich, dieses Faservlies 6 durch poröse Materialien zu ersetzen. Wichtig ist die Tatsache, daß die Porengröße < 0,1 µm und der Atemwiderstand < 4,0 cm Wassersäule beträgt.Before a filter holding member 5 with non-woven fabric 6, a mouthpiece 2 is arranged with an inhalation valve 3 and exhaust valve. 4 The nonwoven fabric 6 can be made of natural, synthetic or glass fibers. It is also possible to replace this nonwoven fabric 6 with porous materials. It is important to note that the pore size is <0.1 µm and the breathing resistance is <4.0 cm water column.
Nach 5 bis 15minütiger Atmung, bei der die Ausatemluft 1 durch die erfindungsgemäße Vorrichtung geleitet wird und als Abluft 7 verläßt, wird das Faservlies 6 mit einer Pinzette entnommen und durch Zusammenfalten in den oberen Teil eines Zentrifugenröhrchens überführt sowie 200 bis 400 µl Elutionslösung (z. B. ELISA- Puffer, Salzlösungen, organische Lösungsmittel) auf das obere Ende des Faservlieses 6 gegeben. Anschließend erfolgt eine kurze Zentrifugation bei 500 bis 3000 g. Das so gewonnene Eluat enthält die Lungeninhalts stoffe. Die Bestimmung der Konzentration oder Gesamtmenge der Lungeninhaltsstoffe wird anschließend mit bekannten analy tischen Verfahren (z. B. ELISA, RIA, HPLC oder spektroskopische Verfahren) vorgenommen.After 5 to 15 minutes of breathing, in which the exhaled air 1 is passed through the device according to the invention and leaves as exhaust air 7 , the nonwoven fabric 6 is removed with tweezers and folded into the upper part of a centrifuge tube, and 200 to 400 μl of elution solution (e.g. B. ELISA buffer, salt solutions, organic solvents) on the upper end of the nonwoven 6 . This is followed by a short centrifugation at 500 to 3000 g. The eluate obtained in this way contains the pulmonary substances. The determination of the concentration or total amount of the pulmonary constituents is then carried out using known analytical methods (e.g. ELISA, RIA, HPLC or spectroscopic methods).
Als Indikator der antiinflammatorischen Effektivität des an gewandten Therapieregimes bei Patienten mit Asthma bronchiale wird Leukotrien B4 verwendet. In dem isolierten Lungenaerosol wird die Konzentration oder Menge von Leukotrien B4 mit einem kommerziellen ELISA oder RIA bestimmt. Die Konzentration von Leukotrien B4 im Lungenaerosol ist bei Patienten mit Asthma bronchiale in Abhängigkeit vom Asthmastadium bis zu etwa 10 mal höher als bei gesunden Probanden.As an indicator of the anti-inflammatory effectiveness of the therapy regimen in patients with bronchial asthma leukotriene B4 is used. In the isolated lung aerosol the concentration or amount of leukotriene B4 with a commercial ELISA or RIA. The concentration of Leukotriene B4 in the pulmonary aerosol is in patients with asthma bronchial depending on the asthma stage up to about 10 times higher than in healthy subjects.
Zur Bestimmung des Leukotrien B4 werden 50 µl des unverdünn ten oder bei höheren Konzentrationen des verdünnten Materials eingesetzt.To determine the leukotriene B4, 50 µl of the undiluted or at higher concentrations of the diluted material used.
Die ermittelten Leukotrien B4-Werte werden mit denen gesunder Probanden verglichen. Das Therapieregime für die Patienten mit Asthma bronchiale wird anhand dieser Daten so optimiert, daß die Leukotrien B4-Werte denen gesunder Probanden angenähert werden. The determined leukotriene B4 values are compared with those compared healthy subjects. The therapy regime for the Patients with bronchial asthma will do so based on this data optimizes that the leukotriene B4 values are more healthy than those Subjects are approximated.
11
Ausatemluft
Exhaled air
22nd
Mundstück
Mouthpiece
33rd
Einatemventil
Inhalation valve
44th
Auslaßventil
Exhaust valve
55
Filterhalterung
Filter holder
66
Faservlies
Nonwoven
77
Abluft
Exhaust air
Claims (9)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1997118924 DE19718924A1 (en) | 1997-04-28 | 1997-04-28 | Apparatus to recover component fractions from exhaled air |
| DE1997142331 DE19742331A1 (en) | 1997-04-28 | 1997-09-19 | Recovery of constituents from exhaled air |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1997118924 DE19718924A1 (en) | 1997-04-28 | 1997-04-28 | Apparatus to recover component fractions from exhaled air |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19718924A1 true DE19718924A1 (en) | 1998-10-29 |
Family
ID=7828660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1997118924 Withdrawn DE19718924A1 (en) | 1997-04-28 | 1997-04-28 | Apparatus to recover component fractions from exhaled air |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE19718924A1 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012006250A1 (en) | 2010-07-06 | 2012-01-12 | Deton Corp. | System for airborne bacterial sample collection and analysis |
| CN102498398A (en) * | 2009-09-09 | 2012-06-13 | 森撒部伊斯公司 | Drug detection in exhaled breath |
| WO2013132085A1 (en) * | 2012-03-08 | 2013-09-12 | Sensa Bues Ab | A portable sampling device and method for detection of biomarkers in exhaled breath |
| EP2706355A1 (en) * | 2012-09-11 | 2014-03-12 | Sensa Bues AB | System and method for eluting and testing substance from exhaled aerosol sample |
| CN104939831A (en) * | 2010-09-09 | 2015-09-30 | 森撒部伊斯公司 | System and method for collecting samples in exhaled gas of subject and uses of method |
| EP1377815B1 (en) * | 2001-04-11 | 2015-12-30 | Rapid Biosensor Systems Limited | Biological measurement system and method of its use. |
| US9977011B2 (en) | 2011-03-09 | 2018-05-22 | Sensa Bues Ab | Portable sampling device and method for sampling drug substances from exhaled breath |
| US10080857B2 (en) | 2013-03-12 | 2018-09-25 | Deton Corp. | System for breath sample collection and analysis |
| CN109752232A (en) * | 2017-11-06 | 2019-05-14 | 广州禾信仪器股份有限公司 | Gas-solid separating device |
| USD876257S1 (en) | 2018-05-07 | 2020-02-25 | Sensa Bues Ab | Breath sampling device |
| WO2023205584A1 (en) * | 2022-04-18 | 2023-10-26 | Infinity Biologix Llc | Systems for the collection of viral particles and uses thereof |
-
1997
- 1997-04-28 DE DE1997118924 patent/DE19718924A1/en not_active Withdrawn
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1377815B1 (en) * | 2001-04-11 | 2015-12-30 | Rapid Biosensor Systems Limited | Biological measurement system and method of its use. |
| JP2015057607A (en) * | 2009-09-09 | 2015-03-26 | センサ ビューズ エービー | Medicine detection in exhaled breath |
| US10520439B2 (en) | 2009-09-09 | 2019-12-31 | Sensa Bues Ab | System and method for drug detection in exhaled breath |
| US11567011B2 (en) | 2009-09-09 | 2023-01-31 | Sensa Bues Ab | System and method for drug detection in exhaled breath |
| EP3336543A1 (en) * | 2009-09-09 | 2018-06-20 | Sensa Bues AB | Drug detection in exhaled breath |
| EP2361387B1 (en) * | 2009-09-09 | 2014-04-16 | Sensa Bues AB | Drug detection in exhaled breath |
| EP2765421A1 (en) * | 2009-09-09 | 2014-08-13 | Sensa Bues AB | Drug detection in exhaled breath |
| EP2765420A1 (en) * | 2009-09-09 | 2014-08-13 | Sensa Bues AB | Drug detection in exhaled breath |
| CN102498398B (en) * | 2009-09-09 | 2015-03-11 | 森撒部伊斯公司 | System and method for drug detection in exhaled breath |
| AU2010294183B2 (en) * | 2009-09-09 | 2016-05-26 | Sensa Bues Ab | Drug detection in exhaled breath |
| CN102498398A (en) * | 2009-09-09 | 2012-06-13 | 森撒部伊斯公司 | Drug detection in exhaled breath |
| WO2012006250A1 (en) | 2010-07-06 | 2012-01-12 | Deton Corp. | System for airborne bacterial sample collection and analysis |
| EP2591331A4 (en) * | 2010-07-06 | 2017-06-07 | Deton Corp. | System for airborne bacterial sample collection and analysis |
| US9988691B2 (en) | 2010-07-06 | 2018-06-05 | Deton Corp. | System for airborne bacterial sample collection and analysis |
| CN104939831A (en) * | 2010-09-09 | 2015-09-30 | 森撒部伊斯公司 | System and method for collecting samples in exhaled gas of subject and uses of method |
| CN104939831B (en) * | 2010-09-09 | 2018-11-09 | 森撒部伊斯公司 | The system and method and application thereof of sample are collected from the expiratory air of subject |
| US9977011B2 (en) | 2011-03-09 | 2018-05-22 | Sensa Bues Ab | Portable sampling device and method for sampling drug substances from exhaled breath |
| WO2013132085A1 (en) * | 2012-03-08 | 2013-09-12 | Sensa Bues Ab | A portable sampling device and method for detection of biomarkers in exhaled breath |
| US20150033824A1 (en) * | 2012-03-08 | 2015-02-05 | Sensa Bues Ab | Portable Sampling Device and Method for Detection of Biomarkers in Exhaled Breath |
| US10359417B2 (en) * | 2012-03-08 | 2019-07-23 | Sensa Bues Ab | Portable sampling device and method for detection of biomarkers in exhaled breath |
| US9429564B2 (en) | 2012-09-11 | 2016-08-30 | Sensa Bues Ab | System and method for eluting and testing substance from exhaled aerosol sample |
| WO2014041045A1 (en) | 2012-09-11 | 2014-03-20 | Sensa Bues Ab | System and method for eluting and testing substance from exhaled aerosol sample |
| EP2706355A1 (en) * | 2012-09-11 | 2014-03-12 | Sensa Bues AB | System and method for eluting and testing substance from exhaled aerosol sample |
| US10080857B2 (en) | 2013-03-12 | 2018-09-25 | Deton Corp. | System for breath sample collection and analysis |
| CN109752232A (en) * | 2017-11-06 | 2019-05-14 | 广州禾信仪器股份有限公司 | Gas-solid separating device |
| CN109752232B (en) * | 2017-11-06 | 2023-11-07 | 广州禾信仪器股份有限公司 | Gas-solid separation device |
| USD876257S1 (en) | 2018-05-07 | 2020-02-25 | Sensa Bues Ab | Breath sampling device |
| WO2023205584A1 (en) * | 2022-04-18 | 2023-10-26 | Infinity Biologix Llc | Systems for the collection of viral particles and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0759169B1 (en) | Process and device for collecting expired breath condensate | |
| EP2895855B1 (en) | System and method for eluting and testing substance from exhaled aerosol sample | |
| AU2002362047C1 (en) | Improved breath collection apparatus | |
| JP6332597B2 (en) | Portable sampling device and method for sampling drug substance from exhaled breath | |
| DE102007028831A1 (en) | Breath condensate sampler for use with mechanical respirator for monitoring breathing condition of patient, has condensate collecting device collecting condensate portion of exhaled gas when air-flow valve is in one position | |
| DE19718924A1 (en) | Apparatus to recover component fractions from exhaled air | |
| EP1139870A4 (en) | DEVICE AND METHOD FOR MONITORING ASTHMA | |
| CH638990A5 (en) | DEVICE FOR TRANSFERING BLOOD GAS SAMPLES FROM A BLOOD VESSEL TO A GAS ANALYZER. | |
| DE19718925A1 (en) | Recovery of component fractions from exhaled air | |
| EP3700418A1 (en) | Attachment device and method for a sample collection device for obtaining samples from respiratory air | |
| DE19619763A1 (en) | Device for taking inspiratory and / or expiratory gas samples | |
| DE3932784C2 (en) | Process for the extraction of non-volatile substances as analytical sample material from the human breath | |
| JP2024515320A (en) | Gas or breath sampling device that captures both aerosol and vapor fractions | |
| DE19755471A1 (en) | Device for examining respiratory diseases and diagnostic means | |
| EP3826537A1 (en) | Method for obtaining a breath sample of a test person and device | |
| DE19505504A1 (en) | Collection of exhaled breath sample | |
| EP1731095A2 (en) | Measurement and analysis of components of exhaled respiratory gas | |
| DE19528158A1 (en) | Device for extracting the contents of the exhaled air | |
| DE20001995U1 (en) | Device for analyzing exhaled air and / or for collecting samples | |
| DE102009048644A1 (en) | Apparatus and method for the fractionated recovery of ingredients of the exhaled air | |
| DE10235310B4 (en) | Method for determining allergenic potency of products | |
| DE9421065U1 (en) | Device for collecting exhaled breath condensate | |
| WO2020148030A1 (en) | Apparatus for collecting a gaseous breath sample from a test subject | |
| KR100593871B1 (en) | Wastewater Condensate Collector Using Cooling System | |
| DE102022204390A1 (en) | Device and method for collecting breathing air condensate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8122 | Nonbinding interest in granting licenses declared | ||
| AG | Has addition no. |
Ref country code: DE Ref document number: 19742331 Format of ref document f/p: P |
|
| 8127 | New person/name/address of the applicant |
Owner name: MEDIUM-SENSOR INGENIEUR- UND HANDELSGESELLSCHAFT F |
|
| 8139 | Disposal/non-payment of the annual fee |